Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1501-1520 of 2,251 trials

Oxygen Supply After Non-Cardiac Surgery: AIOLOS Trial

We are studying whether providing extra oxygen helps patients maintain better oxygen levels and improves recovery after non-cardiac surgery. This trial compares supplemental oxygen to standard care in the first days post-surgery.

Postoperative Complications Risk after General SurgeryPostoperative Complications Risk after Urology Surgery1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicinePulmonology

Mixed Dyslipidaemia: Rosuvastatin and Fenofibrate Study

We are comparing two medication combinations to see which one better lowers bad cholesterol in patients with mixed dyslipidaemia at high risk for heart disease. This study will help us understand their effectiveness and safety.

Dyslipidemia3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyEndocrinology

Pancreatic Cancer: Gemcitabine vs. Reduced-Dose Chemotherapy

We are studying whether standard-dose gemcitabine or a reduced-dose combination chemotherapy is more effective for fragile patients with non-resectable pancreatic cancer. This research aims to find the best treatment for those who cannot tolerate full-dose chemotherapy.

Pancreatic Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Primary Sclerosing Cholangitis: Norucholic Acid Tablets

We are studying the safety and tolerability of norucholic acid tablets for people with primary sclerosing cholangitis. We also want to see if it effectively helps manage their condition.

Primary Sclerosing Cholangitis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyHepatology

FAPI PET Imaging for Pleural Mesothelioma

We are studying how effective FAPI PET scans are for diagnosing and staging pleural mesothelioma. This research may help improve treatment decisions and monitoring for patients with this condition.

Pleural Mesothelioma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncologyOtolaryngology

Acute Spinal Cord Injury: NG004 Treatment

We are testing a new antibody treatment for patients with acute spinal cord injuries to see if it is safe and well-tolerated. This study will help us understand how the treatment works in the body.

Cervical Spinal Cord InjurySafety phase (I)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Cystectomy: Targeted Antibiotic Prophylaxis Study

We are testing whether a personalized antibiotic treatment can help reduce hospital readmissions due to infections after bladder surgery. This study compares it to the standard antibiotic approach used during stent removal.

Bacterial Infection3-6 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesInfectious DiseasesUrology

Rheumatoid Arthritis: Adalimumab Tapering Study

We are investigating the lowest effective dose of adalimumab for patients with rheumatoid arthritis in remission. The study also looks at how well patients tolerate the treatment and the development of antibodies.

Rheumatoid Arthritis1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineRheumatology

Trabectedin for HEY1-NOCA2 Positive Mesenchymal Chondrosarcoma

We are studying the effects of trabectedin in adults and young adults with advanced mesenchymal chondrosarcoma who have already received other treatments. The trial aims to assess how well this medication works in reducing tumors and improving patient outcomes.

Mesenchymal Chondrosarcoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Spinocerebellar Ataxia and Huntington’s Disease: VO659 Treatment

We are investigating the safety of a new treatment given through the spine for people with spinocerebellar ataxia types 1 and 3, and Huntington’s disease. This study aims to understand how the body processes the medication.

Spinocerebellar Ataxia Types 1, 3 and Huntington's Disease1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteNeurology

Pseudomyxoma Peritonei: Neoadjuvant Chemotherapy Study

We are studying whether a combination of capecitabine and cyclophosphamide can help patients with large Pseudomyxoma peritonei before surgery. The goal is to see if this treatment improves tumor shrinkage and surgical success.

Pseudomyxoma Peritonei>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Ocular Melanoma: Roginolisib Treatment Study

We are studying the effectiveness of roginolisib for patients with advanced ocular or uveal melanoma compared to standard therapies. The trial will also assess safety and quality of life impacts.

Uveal MelanomaEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyOphthalmology

PRCA Treatment: Isatuximab Study

We are studying whether the drug isatuximab can help patients with pure red cell aplasia after stem cell transplantation. This trial compares its effects to standard supportive care to see which is more effective.

Pure Red Cell Aplasia>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Idiopathic Retroperitoneal Fibrosis: Early Steroid Discontinuation Study

We are investigating whether stopping steroid treatment early in patients with idiopathic retroperitoneal fibrosis affects relapse rates. This study aims to improve treatment strategies for managing this condition.

Idiopathic Retroperitoneal Fibrosis>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineRheumatology

Systemic Lupus Erythematosus: Cenerimod Study

We are examining the long-term safety and tolerability of cenerimod in adults with systemic lupus erythematosus. This study looks at how the medication works alongside existing treatments.

Systemic Lupus Erythematosus>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Diabetic Macular Edema: Dexamethasone Implant Study

We are investigating a new treatment using a dexamethasone implant for patients with diabetic macular edema. The goal is to see if it improves vision and how well patients tolerate the treatment.

Diabetic Macular Oedema>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesEndocrinologyOphthalmology

Breast Cancer: Patritumab Deruxtecan with Pembrolizumab

We are studying a new treatment combination for high-risk early-stage breast cancer patients to see if it improves tumor response compared to standard chemotherapy. This trial will help us understand the safety and effectiveness of this new approach.

Triple Negative Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

PBP1510 for Advanced Pancreatic Cancer

We are studying a new treatment called PBP1510 in patients with advanced pancreatic cancer that has not responded to previous chemotherapy. The trial will evaluate its safety and effectiveness, both alone and with another drug, gemcitabine.

Advanced Pancreatic CancerSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Kidney Transplant: Regulatory T Cell Therapy

We are studying the safety of using regulatory T cells in kidney transplant recipients to see if it helps the body accept the new kidney better. This may allow for less reliance on standard immunosuppressive medications.

Kidney TransplantationSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNephrology

Neovascular AMD: Faricimab Treatment Study

We are exploring whether two initial doses of faricimab can help keep neovascular AMD inactive in treatment-naive patients. The study also looks at factors that may predict disease activity and recurrence.

Age-related Macular Degeneration>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesOphthalmology